Additive Genetic Effects for Schizotypy Support a Fully-Dimensional Model of Psychosis-Proneness
Abstract
Schizotypy is an organization of traits mirroring psychosis-like symptoms and conveying individual psychosis-proneness. Schizotypy and schizophrenia share a genetic basis, wherefore initial schizotypy definitions considered a schizophrenic genotype as a condicio sine qua non. Since the search for a monogenetic schizotypy marker has proven in vain, it is believed that schizotypy is (genetically) based on multiple alleles, each of small effect-size. Schizophrenia may be viewed as a qualitative entity at the extreme of the schizotypy dimension. To date, however, it has not been shown that effects of individual schizotypy-related alleles or genotypes are additive, which would be necessary for the proposition of latent genetic schizotypy factors. Based on previous findings of significant associations of candidate polymorphisms with schizotypy, we chose to examine if these genetic effects were, indeed, additive regarding positive schizotypy. Using a sample of 288 healthy participants we calculated allele-wise and genotype-wise risk indices and examined, whether levels of positive schizotypy would significantly increase with genetic risk. Our findings show significant additive genetic effects of select polymorphisms on positive schizotypy and, thus, support the notion of a fully-dimensional and partially genetically based model of schizotypy.
References
1979). Consanguinity and schizophrenia in Sudan. British Journal of Psychiatry, 134, 635–636.
(2009). Gene-environment interactions predict cortisol responses after acute stress: Implications for the etiology of depression. Psychoneuroendocrinology, 34, 1294–1303.
(2010). The BDNF Val66Met polymorphism affects HPA-axis reactivity to acute stress. Psychoneuroendocrinology, 35, 949–953.
(2002). Genetics of population isolates. Clinical Genetics, 61, 233–247.
(1983). Familial relatedness of schizophrenia and schizotypal states. The American Journal of Psychiatry, 140, 1437–1442.
(2013). Positive and negative schizotypy are associated with prodromal and schizophrenia-spectrum symptoms. Schizophrenia Research, 145, 50–55.
(1995). A family study of schizotypal disorder. Schizophrenia Bulletin, 21, 33–45.
(1991). Psychiatric disorders in the families of schizotypal subjects. Schizophrenia Bulletin, 17, 659–668.
(1994). One and two sided tests of significance. BMJ, 309, 248.
(1997). Creativity and schizotypy. In G. ClaridgeEd., Schizotypy – Implications for Illness and Health (pp. 274–298). Oxford, UK: Oxford University Press.
(1997). Theoretical background and issues. In G. ClaridgeEd., Schizotypy – Implications for Illness and Health (pp. 3–18). Oxford: Oxford University Press.
(2004). The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochemical Research, 29, 1179–1188.
(2009). The rate of consanguineous marriages among parents of schizophrenic patients in the Arab Bedouin population in Southern Israel. The World Journal of Biological Psychiatry, 10, 334–336.
(2013). Dopaminergic basis of the psychosis-prone personality investigated with functional magnetic resonance imaging of procedural learning. Frontiers in Human Neuroscience, 7, 130.
(2012). Ten ironic rules for non-statistical reviewers. Neuroimage, 61, 1300–1310.
(2013). Schizotypie. In M. A. WirtzEd., Dorsch – Lexikon der Psychologie. Bern, Switzerland: Hans Huber.
(2015, in press). Genetic associations: The basis of Schizotypy. In O. MasonG. ClaridgeEds., Schizotypy – new dimensions. ISBN: 978-0-415-72203-2. Oxford, UK: Routledge, Taylor & Francis Group.
(2014). Psychosis-proneness correlates with expression levels of dopaminergic genes. European Psychiatry, 29, 304–306.
(2013). Dopaminergic foundations of schizotypy as measured by the German version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE) – a suitable endophenotype of schizophrenia. Frontiers in Human Neuroscience, 7, Retrieved from http://journal.frontiersin.org/article/10.3389/fn.hum.2013.00001
(2006). Imaging genetics: Perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biological Psychiatry, 59, 888–897.
(1999). Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. The Journal of Neuroscience, 19, 4110–4122.
(2009). The dopamine hypothesis of schizophrenia: Version III – the final common pathway. Schizophrenia Bulletin, 35, 549–562.
(2012). Runs of homozygosity implicate autozygosity as a schizophrenia risk factor. PLoS Genetics, 8, e1002656.
(1995). Schizotypal personality disorder in parents and the risk for schizophrenia in siblings. Schizophrenia Bulletin, 21, 47–52.
(2011). MMPI-2 characteristics of the Old Order Amish: A comparison of clinical, nonclinical, and United States normative samples. Psychological Assessment, 23, 865–875.
(2008). The dimensional structure of the Wisconsin Schizotypy Scales: Factor identification and construct validity. Schizophrenia Bulletin, 34, 444–457.
(2012). The expression of positive and negative schizotypy in daily life: An experience sampling study. Psychological Medicine, 42, 2555–2566.
(2006). Schizotypy – an organizing framework for schizophrenia research. Current Directions in Psychological Science, 15, 162–166.
(2003). A quantitative genetic analysis of schizotypal personality traits. Psychological Medicine, 33, 803–816.
(2006). The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE): Further description and extended norms. Schizophrenia Research, 82, 203–211.
(2010). Consanguinity and increased risk for schizophrenia in Egypt. Schizophrenia Research, 120, 108–112.
(1962). Schizotaxia, Schizotypy, Schizophrenia. The American Psychologist, 17, 827–838.
(2013). Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level. Psychological Medicine, 43, 2547–2562.
(2009). Common disorders are quantitative traits. Nature Reviews. Genetics, 10, 872–878.
(1953). Dynamics and classification of disordered behavior. The American Journal of Psychiatry, 110, 406–416.
(2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 45, 1150–1159.
(1981). Psychopathology and social deviance among Jews. Journal of Jewish Communal Service, 58, 12–23.
(1975). Inbreeding in the population and the spread of schizophrenia in one of the rural regions of Azerbaijan. Genetika, 11, 149–152.
(2013). Variation in psychosis gene ZNF804A is associated with a refined schizotypy phenotype but not neurocognitive performance in a large young male population. Schizophrenia Bulletin, 39, 1252–1260.
(2003). Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Archives of General Psychiatry, 60, 1187–1192.
(1993). Psychiatric illnesses in families of subjects with schizophrenia-spectrum personality disorders: High morbidity risks for unspecified functional psychoses and schizophrenia. The American Journal of Psychiatry, 150, 66–71.
(2010). The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD. BMC Psychiatry, 10, 50.
(2010). The brain-derived neurotrophic factor Val66Met polymorphism affects memory formation and retrieval of biologically salient stimuli. Neuroimage, 50, 1212–1218.
(2009). Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats. Science, 324, 1732–1734.
(2011). Impact on schizotypal personality trait of a genome-wide supported psychosis variant of the ZNF804A gene. Neuroscience Letters, 495, 216–220.
(2014). A population-based study of genetic variation and psychotic experiences in adolescents. Schizophrenia Bulletin, 40, 1254–1262.
(2013). The myth of schizophrenia as a progressive brain disease. Schizophrenia Bulletin, 39, 1363–1372.
(